Market Intelligence Report, Biologic Response Modifier Agents, 2015

This line graph depicts the growth in the sales of biologic DMARDs in Canada and the PMPRB7 from 2010 to 2017. The sales values are indexed to start at a value of one in 2010 and are as follows:

The yearly sales of biologic DMARDs in Canada are given in a small table at the bottom of the graph:

• 2010: $1.1 billion
• 2011: $1.3 billion
• 2012: $1.5 billion
• 2013: $1.8 billion
• 2014: $2.0 billion
• 2015: $2.2 billion
• 2016: $2.5 billion
• 2017: $2.7 billion

This bar graph depicts the biologic DMARD market share of total pharmaceutical sales for Canada and the PMPRB7 countries from 2010 to 2017:

This bar graph gives the 2017 sales of each drug as a percentage of the total biologic DMARD sales for Canada and each of the PMPRB7 countries:

This series of graphs illustrates the trends in Canadian sales of biologic DMARDs, by drug product from 2010 to 2017.

Two bar graphs on the left depict the growth in sales for biologic DMARDs from $1.1 billion in 2010 to $2.7 billion in 2017. The contribution of each individual medicine to this growth is as follows:

• Infliximab: 43%;
• Adalimumab: 31%;
• Etanercept: 3%;
• Rituximab: 6%;
• Golimumab: 9%;
• Abatacept: 3%;
• Tocilizumab: 3%;
• Certolizumab: 2%;
• Anakinra: 0%;
• Sarilumab; 0%.

The area graph on the right depicts the sales of each medicine for each year from 2010 to 2017:

The two pie graphs below give the share of sales of each medicine in 2010 and 2017.

Share of sales in 2010:

• Infliximab: 37.1%;
• Adalimumab: 21.1%;
• Etanercept: 23.3%;
• Rituximab: 14.9%;
• Golimumab: 1.1%;
• Abatacept: 1.9%;
• Tocilizumab: 0.1%;
• Certolizumab: 0.2%;
• Anakinra: 0.2%;
• Sarilumab: 0%.

Share of sales in 2017:

• Infliximab: 40.6%;
• Adalimumab: 26.7%;
• Etanercept: 11.8%;
• Rituximab: 9.5%;
• Golimumab: 5.5%;
• Abatacept: 2.5%;
• Tocilizumab: 2.0%;
• Certolizumab: 1.5%;
• Anakinra: 0%;
• Sarilumab: 0.1%.

This bar graph gives the average annual treatment cost per beneficiary (excluding markup and dispensing costs) in public drug plans from 2010 to 2017. Treatment costs are given for each biologic DMARD and for the class average.

The accompanying table below the graph gives additional information for each drug

This bar graph gives the 2017 bilateral foreign-to-Canadian price ratios for biologic DMARDs for each of the PMPRB7 countries, as well as the multilateral foreign-to-Canadian price ratios for the PMPRB7 and Organisation for Economic Co-operation and Development median prices. Foreign prices are compared to the Canadian price level, which is set to one.

France: 0.64; Germany: 0.93; Italy: 0.75; Sweden: 0.81; Switzerland: 1.01; United Kingdom: 0.65; United States: 1.70; PMPRB7 median: 0.82; Organisation for Economic Co-operation and Development median: 0.71.

This graph gives the 2017 foreign-to-Canadian price ratios by biologic DMARD for the PMPRB7 and Organisation for Economic Co-operation and Development countries. The Canadian price (which is given in the table below the graph) is set to one and the international measures reported relative to this value. On the graph, the price ranges for the six European countries in the PMPRB7 are represented by rectangular boxes. The median PMPRB7 price, the median Organisation for Economic Co-operation and Development price, and the average United States price are also reported.

This graph gives the 2017 annual treatment costs for biologic DMARDs for Canada, as well as the PMPRB7 and Organisation for Economic Co-operation and Development countries. The ranges in treatment costs for the six European countries in the PMPRB7 are represented by rectangular boxes. The average Canadian treatment cost, the median PMPRB7 cost, the median Organisation for Economic Co-operation and Development cost and the average United States treatment cost are also provided.

This graph compares the 2017 Canadian consumption rates for biologic DMARDs to the rates in the PMPRB7 countries. The ranges in consumption rates for the six European countries in the PMPRB7 are represented by rectangular boxes. The average Canadian, average United States and median PMPRB7 consumption rates are also given. Consumption rates are measured as the number of annual doses per one million inhabitants.